T cells require TRAIL for optimal graft-versus-tumor activity.
about
The cytolytic molecules Fas ligand and TRAIL are required for murine thymic graft-versus-host diseaseTRAIL receptor signaling regulation of chemosensitivity in vivo but not in vitroThe biology of graft-versus-host disease: experimental systems instructing clinical practice.Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosisNKT cell-dependent leukemia eradication following stem cell mobilization with potent G-CSF analogs.Transduction of tumor necrosis factor-related apoptosis-inducing ligand into hematopoietic cells leads to inhibition of syngeneic tumor growth in vivo.Perforin: more than just a pore-forming protein.A cytokine-mediated link between innate immunity, inflammation, and cancer.Alpha-fetoprotein triggers hepatoma cells escaping from immune surveillance through altering the expression of Fas/FasL and tumor necrosis factor related apoptosis-inducing ligand and its receptor of lymphocytes and liver cancer cellsHDAC inhibition and graft versus host diseaseTracking death dealing by Fas and TRAIL in lymphatic neoplastic disorders: pathways, targets, and therapeutic tools.TRAIL and apoptosis induction by TNF-family death receptors.Remodeling specific immunity by use of MHC tetramers: demonstration in a graft-versus-host disease model.Pathophysiology of acute graft-versus-host disease: recent advances.TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor developmentTNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer.Proteasome inhibition and allogeneic hematopoietic stem cell transplantation: a reviewEffector memory CD4+ T cells mediate graft-versus-leukemia without inducing graft-versus-host disease.The TRAIL to targeted therapy of breast cancer.The role of death receptor ligands in shaping tumor microenvironment.TRAIL receptor-targeted therapeutics: resistance mechanisms and strategies to avoid them.[(18)F]FHBG PET/CT Imaging of CD34-TK75 Transduced Donor T Cells in Relapsed Allogeneic Stem Cell Transplant Patients: Safety and Feasibility.Concise review: acute graft-versus-host disease: immunobiology, prevention, and treatment.Adoptively transferred TRAIL+ T cells suppress GVHD and augment antitumor activityT cell repertoire complexity is conserved after LLME treatment of donor lymphocyte infusionsTargeting minor histocompatibility antigens in graft versus tumor or graft versus leukemia responses.Targeting deacetylases to improve outcomes after allogeneic bone marrow transplantation.Manipulating the immune system for anti-tumor responses and transplant tolerance via mixed hematopoietic chimerism.Acute graft-versus-host disease: are we close to bringing the bench to the bedside?Genetically engineered donor T cells to optimize graft-versus-tumor effects across MHC barriers.PKCtheta is required for alloreactivity and GVHD but not for immune responses toward leukemia and infection in mice.Emerging apoptosis agonists for bladder cancer.GVHD prevention: an ounce is better than a pound.Targeting of the tumor necrosis factor receptor superfamily for cancer immunotherapy.Real-time detection of cellular death receptor-4 activation by fluorescence resonance energy transfer.BCR-ABL regulates death receptor expression for TNF-related apoptosis-inducing ligand (TRAIL) in Philadelphia chromosome-positive leukemia.Tumor suppressor IRF-1 mediates retinoid and interferon anticancer signaling to death ligand TRAILResistance of MLL-AFF1-positive acute lymphoblastic leukemia to tumor necrosis factor-alpha is mediated by S100A6 upregulationDonor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity.Blazing a new TRAIL in hematopoietic cell transplantation
P2860
Q33559627-0ADE1CBC-F22A-4CD8-B7B2-CF355BA651FEQ33802751-6D251708-22A7-43A6-A031-22660EBB8DBEQ33917175-D512A356-5C0F-4A61-A5BC-9A9ED58F7969Q33991741-2591B5E6-A960-49AD-9F5E-D15A048DE56FQ34078681-F205FF17-A884-404E-ACCE-BF34829DFAA7Q34139621-2D4E3C8B-08D1-42DC-8C17-0A2424321CE0Q34616180-2AF835F7-8B4F-4E1E-AA4D-948553DEF09DQ34625152-F0C2269A-B490-492F-939F-0648159E06C5Q35010607-6CFD6893-E172-4933-993F-E2BF54D47049Q35016985-22C23D44-61EA-4206-8BAB-B968DA3DD393Q35209364-FD481159-F0B8-436D-8938-33D2F11F24A1Q35591708-0D297F9F-8691-4877-A0CF-84FDA1628E4BQ35849455-CF897A5B-3E44-46D5-96E2-3E348C882162Q36156559-1D22CDC3-0F0C-405F-A017-BD59ACE57329Q36249542-7CAEBB57-1452-4E36-AD2F-F49536CB2927Q36365504-5D47BF31-C061-4874-B7AF-CC682F96EBD5Q36408216-05E08508-6A47-4399-8AD8-DC8961086A94Q36445956-B25066A0-2121-44CA-AB91-EAC9ADA4B12DQ36511919-864B6EA9-70B2-4D86-8081-D959A26AFD13Q36693120-3727DF42-320C-472C-9C30-5E8B5D9D3D70Q36731174-B825F28F-B4E6-4347-BD52-A831A42E6A9EQ36756712-D8D0943D-3291-4C11-865C-79CC0C960445Q36861714-C3AA18B8-2578-4AB5-80D9-B7DEE4DA1F67Q36891101-276B19ED-1775-4CAB-BED2-A7F9ECE6D2F0Q36986447-7DFC0034-C588-4DB4-8172-015F72B598D6Q36994811-EEB00635-C22A-488B-A4D4-7A3F5DFE6DE8Q37026059-5D37F849-4D7C-4F6C-A2DE-3354E25A5919Q37211290-61621D22-D3AC-496C-8E4C-AC248D28C4BEQ37402799-5FD48A13-8BC1-42BE-BF46-38789BA98353Q37416883-9AF8ECA2-D4A3-4717-8938-B13C0A141ED6Q37452305-7588F4DE-DE53-48CE-81EF-E066F9E16704Q37601481-1034F622-E7E7-4F05-B089-E0F49714E571Q37973859-09AA3299-E316-42EA-8944-31DA46CB8174Q38120535-5DB56E4E-BED2-43FC-8BC1-A98C1DA8F16FQ39226276-3DF8E483-74C9-4193-B901-789A48905422Q39337116-A7369A31-E737-48EF-8D30-2AF5A1215EBDQ39958722-FF02B04B-DB64-475C-8437-ABB7DE6D05E0Q40350461-D8A55365-2609-4D60-BACB-AF31AF23F16DQ41131801-FC423609-A68E-45D5-8B23-72AD018FAD95Q41285619-7A91FF1A-329C-4867-8560-BCB9CCCDF2B9
P2860
T cells require TRAIL for optimal graft-versus-tumor activity.
description
2002 nî lūn-bûn
@nan
2002 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
T cells require TRAIL for optimal graft-versus-tumor activity.
@ast
T cells require TRAIL for optimal graft-versus-tumor activity.
@en
T cells require TRAIL for optimal graft-versus-tumor activity.
@nl
type
label
T cells require TRAIL for optimal graft-versus-tumor activity.
@ast
T cells require TRAIL for optimal graft-versus-tumor activity.
@en
T cells require TRAIL for optimal graft-versus-tumor activity.
@nl
prefLabel
T cells require TRAIL for optimal graft-versus-tumor activity.
@ast
T cells require TRAIL for optimal graft-versus-tumor activity.
@en
T cells require TRAIL for optimal graft-versus-tumor activity.
@nl
P2093
P2860
P356
P1433
P1476
T cells require TRAIL for optimal graft-versus-tumor activity.
@en
P2093
Andrew S Greenberg
Barry J Kappel
Cornelius Schmaltz
George F Murphy
Henning Walczak
Jacques J Peschon
James M Crawford
Jeffrey M Eng
Jennifer Ongchin
Jimmy A Rotolo
P2860
P2888
P304
P356
10.1038/NM1202-797
P407
P50
P577
2002-11-11T00:00:00Z